Circulating tumor DNA outperforms circulating tumor cells for KRAS mutation detection in thoracic malignancies

Clinical Chemistry

Volumn 61, Issue 10, 2015, Pages 1299-1304

  Freidin, Maxim B ^a,b   Freydina, Dasha V ^a,b   Leung, Maria ^a   Fernandez, Angeles Montero ^a   Nicholson, Andrew G ^a,b   Lim, Eric ^a,b  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHLOROPLAST DNA; DNA; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ADULT; ALLELE; ARTICLE; CANCER RESEARCH; CIRCULATING TUMOR CELL; CODON; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; FALSE NEGATIVE RESULT; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LIMIT OF DETECTION; LUNG CANCER; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; ONCOGENE K RAS; PNEUMOTHORAX; POLYMERASE CHAIN REACTION; PYROSEQUENCING; SENSITIVITY AND SPECIFICITY; AGED; BLOOD; COMPARATIVE STUDY; GENETICS; LUNG; LUNG TUMOR; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROCEDURES; TUMOR EMBOLISM;

AGED; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASTIC CELLS, CIRCULATING; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SENSITIVITY AND SPECIFICITY;

EID: 84942888495     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2015.242453     Document Type: Article

References (20)

1. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 2013;10:472-84.
2. Alix-Panabières C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin Chem 2013;59:110-8.
3. Punnoose EA, Atwal S, Liu W, Raja R, Fine BM, Hughes BG, et al. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res 2012; 18:2391-401.
4. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013;368:1199-209.
5. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawa IN, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014;6:224ra24.
6. Yu M, Stott S, Toner M, Maheswaran S, Haber DA. Circulating tumor cells: approaches to isolation and characterization. J Cell Biol 2011;192:373-82.
7. Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014;32:579-86.
8. Santis G, Angell R, Nickless G, Quinn A, Herbert A, Cane P, et al. Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR. PLoS One 2011;6:e25191.
9. Mancini I, Santucci C, Sestini R, Simi L, Pratesi N, Cianchi F, et al. The use of COLD-PCR and high-resolution melting analysis improves the limit of detection of KRAS and BRAF mutations in colorectal cancer. J Mol Diagn 2010;12:705-11.
10. Castellanos-Rizaldos E, Liu P, Milbury CA, Guha M, Brisci A, Cremonesi L, et al. Temperature-tolerant COLDPCR reduces temperature stringency and enables robust mutation enrichment. Clin Chem 2012;58: 1130-8.
11. Song C, Milbury CA, Li J, Liu P, Zhao M, Makrigiorgos GM. Rapid and sensitive detection of KRAS mutation after fast-COLD-PCR enrichment and high-resolution melting analysis. Diagn Mol Pathol 2011;20:81-9.
12. Li J, Wang L, Mamon H, Kulke MH, Berbeco R, Makrigiorgos GM. Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nat Med 2008;14:579-84.
13. Dwight Z, Palais R, Wittwer CT. uMELT: prediction of high-resolution melting curves and dynamic melting profiles of PCR products in a rich web application. Bioinformatics 2011;27:1019-20.
14. Chongsuvivatwong V. epicalc: Epidemiological calculator. http://CRAN.R-project.org/package=epicalc (Accessed September 2014).
15. Schaarschmidt F. bdpv: Inference and design for predictive values in binary diagnostic tests. http://CRAN.Rproject.org/package=bdpv (Accessed September 2014).
16. Fernandez SV, Bingham C, Fittipaldi P, Austin L, Palazzo J, Palmer G, et al. TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients. Breast Cancer Res 2014;16:445.
17. Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J, et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 2014;346:256-9.
18. Freidin MB, Tay A, Freydina DV, Chudasama D, Nicholson AG, Rice A, et al. An assessment of diagnostic performance of a filter-based antibody-independent peripheral blood circulating tumour cell capture paired with cytomorphologic criteria for the diagnosis of cancer. Lung Cancer 2014;85:182-5.
19. Milbury CA, Li J, Makrigiorgos GM. Ice-COLD-PCR enables rapid amplification and robust enrichment for low-abundance unknown DNA mutations. Nucleic Acids Res 2011;39:e2.
20. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008;455: 1069-75.